We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MEDICA 2024 to Highlight Hot Topics of MedTech Industry

By LabMedica International staff writers
Posted on 08 Nov 2024

Once again this year, everything at MEDICA (Düsseldorf, Germany) will revolve around the major trends and challenges in medical technology. More...

The focus will be on four key topics that will have a lasting impact on the industry: Artificial Intelligence & Big Data, Robotics & Assistive Systems, Connected Care, and Skills Shortage & Staff Development.

The integration of artificial intelligence (AI) and big data into medical technology is revolutionizing healthcare. From precise diagnostics and personalized treatment plans to accelerated drug research – AI and big data are opening doors to new possibilities. At MEDICA 2024, visitors will have the chance to experience exciting solutions and research approaches that raise the efficiency and accuracy of medical procedures to a new level. Experts will present how these technologies support precise navigation during surgical procedures or optimize diagnoses by analyzing large amounts of data. Robotics and assistive systems are changing the way medical treatments are performed. At MEDICA 2024, attendees will experience how surgical robots make minimally invasive procedures more precise and rehabilitation robots speed up the recovery process. These technologies not only offer enormous added value for patients but also relieve the burden on medical staff. Visitors will be inspired by the latest developments that take efficiency and patient safety in the healthcare industry to a new level.

In an increasingly digitalized world, connected care plays a key role in medical technology. The combination of medical devices, digital platforms, and real-time data enables optimized patient care. At MEDICA 2024, everything revolves around connected solutions that enable precise diagnoses and treatments through wearables and implants. Connected care not only offers new possibilities for the treatment of patients but also supports medical professionals in making decisions more efficiently. The shortage of skilled workers poses considerable challenges for the medical technology industry. At MEDICA 2024, visitors will find out how companies are tackling this problem with innovative approaches to personnel development. Training programs, further education offers, and strategic personnel planning are crucial for attracting qualified specialists and retaining them in the long term. Attendees can learn from leading experts how targeted measures can secure the future of medical technology and what the current trends are in the field of personnel development.

Related Links:
MEDICA


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.